The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

Dubai Science Park the regions leading science-focused ecosystem will contribute to knowledge-building efforts enabling life ...

Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...

StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

David Li, an analyst from Bank of America Securities, maintained the Hold rating on BeiGene (ONC – Research Report). The associated price ...